NLS Pharmaceutics AG (NLSPW) - Total Liabilities
Based on the latest financial reports, NLS Pharmaceutics AG (NLSPW) has total liabilities worth $1.46 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NLS Pharmaceutics AG cash conversion from operations to assess how effectively this company generates cash.
NLS Pharmaceutics AG - Total Liabilities Trend (2017–2024)
This chart illustrates how NLS Pharmaceutics AG's total liabilities have evolved over time, based on quarterly financial data. See NLSPW total equity for net asset value and shareholders' equity analysis.
NLS Pharmaceutics AG Competitors by Total Liabilities
The table below lists competitors of NLS Pharmaceutics AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ordinary Fully Paid Deferred Settlement
AU:EDEDA
|
Australia | AU$17.73 Million |
|
Carbon Revolution Public Limited Ordinary Shares
NASDAQ:CREV
|
USA | $218.58 Million |
|
Lucy Scientific Discovery Inc.
NASDAQ:LSDIF
|
USA | $4.21 Million |
|
Seed Capital Solutions Plc
LSE:SCSP
|
UK | GBX28.00K |
|
Future Lifestyle Fashions Limited
NSE:FLFL
|
India | Rs57.96 Billion |
|
Tarrina Resources Limited
AU:TR8
|
Australia | AU$1.04 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down NLS Pharmaceutics AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NLSPW market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NLS Pharmaceutics AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NLS Pharmaceutics AG (2017–2024)
The table below shows the annual total liabilities of NLS Pharmaceutics AG from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $826.76K | -92.26% |
| 2023-12-31 | $10.68 Million | +78.13% |
| 2022-12-31 | $6.00 Million | +14.81% |
| 2021-12-31 | $5.22 Million | -48.78% |
| 2020-12-31 | $10.20 Million | +48.46% |
| 2019-12-31 | $6.87 Million | -23.35% |
| 2018-12-31 | $8.96 Million | -10.46% |
| 2017-12-31 | $10.01 Million | -- |
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity … Read more